Home | Value-Based Cancer Care

Featured Content

Navigating Care Programs in the Post-OCM era

Since OCM ended in June of 2022, oncology practice leaders have navigated complex decisions about how to offer patients high-quality, value-driven cancer care and in which reimbursement programs they will participate.

View Content
Featured Video

The Future of Cancer Care Delivery

The future of cancer care delivery is shifting from fee-for-service to a value-based care approach.

View Content
Featured Article

Research Indicates Fewer People Understand the Link Between HPV and Certain Cancers

Vaccination against human papillomavirus (HPV) can prevent several types of cancer, including cervical, oral/oropharyngeal, penile, and anal cancers.

View Content
Listen to our AVBCC Podcasts

Now you can take the Association for Value-Based Cancer Care (AVBCC) on the go with AVBCC podcasts. As healthcare professionals, it can be hard to find time in your busy schedule to stay up-to-date on oncology trends. Now you can receive trusted information from top industry leaders in an easy-to-listen format.

View Content

Top Trending Articles

1.

Liquid Biopsies on the Horizon for Children With Solid Cancers

2.

Improving Diversity in Clinical Trials

3.

Physician Debate: Is Chemotherapy Still the Backbone for CCA Treatment?

FDA Approvals, News & Updates

FDA Approves Columvi for Select Patients With Relapsed or Refractory Large B-Cell Lymphomas

Epkinly FDA Approved for Treatment of Advanced Diffuse Large B-Cell Lymphoma

Lonsurf Receives New Indication, in Combination With Bevacizumab, for Previously Treated Metastatic Colorectal Cancer

View More Articles

Highlights from the Latest Issue: August 2023, Vol 14, No 4

August 2023, Vol 14, No 4

Improving Diversity in Clinical Trials

By Phoebe Starr

Survey Offers Snapshot of Patient and Provider Perceptions of AI Use in Healthcare

Partnering With Patients Key to Improving Healthcare Outcomes

By Phoebe Starr

Ribociclib Plus Endocrine Therapy Improves Invasive Disease-Free Survival in Patients With HR-Positive, HER2-Negative, Early Breast Cancer

By Phoebe Starr

Hematologic Malignancies

Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS

Chicago, IL—Interim results from the phase 3 COMMANDS trial demonstrated that first-line treatment with luspatercept-aamt (Reblozyl) increased hemoglobin levels and enabled nearly twice as many patients with transfusion-dependent, lower-risk myelodysplastic syndromes (MDS) to avoid red blood cell transfusions during the first 24 weeks of the study compared with standard-of-care epoetin alfa.

Quick Quiz: Chronic Myeloid Leukemia

Quick Quiz: Chronic Myeloid Leukemia

Chronic myeloid leukemia, also known as chronic myelogenous leukemia, is a malignancy that originates in blood-forming cells (called myeloid cells) found in bone marrow. How much do you know about chronic myeloid leukemia?

Value-Based Care

Survey Shows Inflation Affecting Majority of Consumer Healthcare Decisions

Breast Reconstruction Disparities Improve Significantly with Medicaid Expansion

Walter Alexander

Innovative Technology Supports Value-Based Care Success

Amy Valley, PharmD

The Alliance for Innovation in Integrated Healthcare Provides New Forum for Stakeholders

View More Articles

Personalized Medicine | Browse By Specialty

We Want to Know

Latest Videos

Bringing Stakeholders Together Bringing Stakeholders Together

Bringing Stakeholders Together Bringing Stakeholders Together

Navigating Care Programs in the Post-OCM era

Navigating Care Programs in the Post-OCM era

View More Videos

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

VBCC Print Edition

VBCC Weekly e‑Newsletter

I have reviewed and consent to the terms of VBCC's Privacy Policy, and VBCC has my permission to retain my information in its database, and to forward pertinent communications to me.